Posts by Adam Lessler
PreludeDxTM Closes $20 Million in Funding to Advance Growth Initiatives and Development of Its Precision Medicine Portfolio
Evidity Health Capital to Join Board of Directors LAGUNA HILLS, Calif., March 22, 2022 /PRNewswire/– Prelude Corporation (PreludeDxTM), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that it has closed a $20 million funding round led by Evidity Health Capital and joined by existing and new investors. Alejandro Sanchez,…
Read MoreAkili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I
Akili’s leading digital therapeutic platform combines science and technology to address cognitive impairments in patients, reimagining how central nervous system medicines are designed, developed, and delivered Transaction will support commercial launch of EndeavorRx®, a first-of-its-kind, FDA-cleared and CE-marked prescription digital therapeutic for pediatric ADHD, as well as advance clinical development pipeline across multiple neuropsychiatric diseases,…
Read MoreAkili Secures $160 Million in Financing; Poised to Deliver on the Promise of Digital Therapeutics
May 26, 2021
Read MoreHaemonetics To Acquire Cardiva Medical, Inc. To Expand Hospital Portfolio
January 20, 2021
Read MoreBiotheranostics Announces Inclusion of Breast Cancer Index™ in the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines for Prediction of Benefit from Extended Endocrine Therapy
January 19, 2021
Read MoreHologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers, for Approximately $230 Million
January 5, 2021
Read More